<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00277589</url>
  </required_header>
  <id_info>
    <org_study_id>L_9133</org_study_id>
    <nct_id>NCT00277589</nct_id>
  </id_info>
  <brief_title>LISA-study : Levothyroxin in Nodular Goiter</brief_title>
  <official_title>TSH-adapted Therapy in a Large Randomized, Observer-blind, Placebo-controlled, Prospective Treatment Study of Patients With Nodular Goiter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:

        -  To evaluate change in total volume of all nodules.

      Secondary objectives:

        -  To evaluate change in goiter volume after a 12-months treatment, number of nodules and
           echogenicity of nodules.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is to compare the change in total volume of all nodules after 12 months Levothyroxin treatment to the change after 12 months of each of the reference treatments (one of the two active controls or placebo)</measure>
    <time_frame>after 12 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in goitre volume after Levothyroxin treatment will be compared to that after each reference treatment after 12 months treatment.</measure>
    <time_frame>after 12 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additionally, the change in the number of nodules after Levothyroxin treatment will be compared to each reference treatment after 12 months treatment.</measure>
    <time_frame>after 12 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echogenicity of the nodules after Levothyroxin treatment will be compared to each reference treatment after 12 months treatment.</measure>
    <time_frame>after 12 months treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1024</enrollment>
  <condition>Goiter, Nodular</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxin-Na</intervention_name>
    <description>1 tablet 30 minutes before breakfast</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine-Na + iodide</intervention_name>
    <description>1 tablet 30 minutes before breakfast</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodide</intervention_name>
    <description>1 tablet 30 minutes before breakfast</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet 30 minutes before breakfast</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian

          -  Normal TSH value (target range between 0.6 - 3.0 mU/l)

          -  Thyroid nodules in a normal sized or enlarged thyroid at least one nodule
             (smaller/equal 20 % of volume with cystic change) with greater/equal 1.0 cm diameter,
             for nodules greater 1.0 cm the diagnosis must be performed according to the guideline
             for diagnostic standards of thyroid disorders.

        Exclusion Criteria:

          -  Thyroid therapy within the last 3 years

          -  Known focal or diffuse structure autonomous thyroid

          -  Contraindication to iodine

          -  Concomitant treatment with iodine containing medication (i.e. amiodarone)

          -  Use of iodine-containing contrast medium within the last 6 weeks

          -  Presence of TPO antibodies (maximum two fold normal value)

          -  Symptomatic coronary heart disease

          -  Endocrine orbitopathy

          -  Known autoimmune thyreopathy

          -  Former radioiodine therapy or surgery

          -  Dermatitis herpetiformis

          -  Pathological laboratory results

          -  Participation in another clinical study with investigational medication within the
             last 30 days

          -  Pregnant or nursing female patients

          -  Female patients of childbearing potential, not using and not willing to continue using
             a medically reliable method of contraception for the entire study duration, such as
             oral, injectable, or implantable contraceptives, or intrauterine contraceptive
             devices, unless they are surgically sterilized/hysterectomized or who are not using
             any other method considered sufficiently reliable by the investigator in individual
             cases.

          -  Severe or unstable cardiovascular diseases (e.g. severe angina pectoris,
             postmyocardial infarction syndrome and ventricular extrasystoles, symptomatic coronary
             heart disease), clinically relevant renal or hepatic diseases or disorders, any other
             clinically relevant condition that might enhance the risk for the study participant.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrin Roscher</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2006</study_first_submitted>
  <study_first_submitted_qc>January 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2006</study_first_posted>
  <last_update_submitted>December 3, 2009</last_update_submitted>
  <last_update_submitted_qc>December 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goiter</mesh_term>
    <mesh_term>Goiter, Nodular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

